Investors
A proven track record of value creation
Our diversified business model allows us to respond to opportunities, while delivering for our stakeholders.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
H1 2025 Interim Results
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Press Release, Financial Results
07 August 2025
- Hikma confirms 2025 guidance and updates medium-term growth outlook Press Release, Financial Results 06 November 2025 Hikma confirms 2025 guidance and updates medium-term growth outlook
- Hikma Pharmaceuticals announces the launch of STARJEMZA™ (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection Press Release, Product 06 November 2025 Hikma Pharmaceuticals announces the launch of STARJEMZA™ (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection
- Hikma R&D. Innovating analytical development. Meet Edvin Brusač Story, Life at Hikma 23 October 2025 Hikma R&D. Innovating analytical development. Meet Edvin Brusač
- Hikma R&D. Innovating formulation development. Meet Anas Abdull-kareem Younues Story, Life at Hikma 15 October 2025 Hikma R&D. Innovating formulation development. Meet Anas Abdull-kareem Younues
